Evidence map›Paper›PMID 26607309›Full record

ArticleClinical and vaccine immunology : CVI2015

Evaluation of a Fiber-Modified Adenovirus Vector Vaccine against Foot-and-Mouth Disease in Cattle.

Gisselle N Medina, Nestor Montiel, Fayna Diaz-San Segundo, Diego Sturza, Elizabeth Ramirez-Medina, Marvin J Grubman, Teresa de los Santos

Open access · diamondAbstract readEvaluation Study
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Gisselle N MedinaPlum Island Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Northeast Area, Greenport, New York, USA.
Nestor MontielPlum Island Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Northeast Area, Greenport, New York, USA Oak Ridge Institute for Science and Education, Plum Island Animal Disease Center Research Participation Program, Oak Ridge, Tennessee, USA.
Fayna Diaz-San SegundoPlum Island Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Northeast Area, Greenport, New York, USA.
Diego SturzaPlum Island Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Northeast Area, Greenport, New York, USA Oak Ridge Institute for Science and Education, Plum Island Animal Disease Center Research Participation Program, Oak Ridge, Tennessee, USA.
Elizabeth Ramirez-MedinaPlum Island Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Northeast Area, Greenport, New York, USA Oak Ridge Institute for Science and Education, Plum Island Animal Disease Center Research Participation Program, Oak Ridge, Tennessee, USA.
Marvin J GrubmanPlum Island Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Northeast Area, Greenport, New York, USA.
Teresa de los SantosPlum Island Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Northeast Area, Greenport, New York, USA teresa.delossantos@ars.usda.gov.
Plum Island Animal Disease Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel vaccination approaches against foot-and-mouth disease (FMD) include the use of replication-defective human adenovirus type 5 (Ad5) vectors that contain the capsid-encoding regions of FMD virus (FMDV). Ad5 containing serotype A24 capsid sequences (Ad5.A24) has proved to be effective as a vaccine against FMD in livestock species. However, Ad5-vectored FMDV serotype O1 Campos vaccine (Ad5.O1C.2B) provides only partial protection of cattle against homologous challenge. It has been reported that a fiber-modified Ad5 vector expressing Arg-Gly-Asp (RGD) enhances transduction of antigen-presenting cells (APC) in mice. In the current study, we assessed the efficacy of a fiber-modified Ad5 (Adt.O1C.2B.RGD) in cattle. Expression of FMDV capsid proteins was superior in cultured cells infected with the RGD-modified vector. Furthermore, transgene expression of Adt.O1C.2B.RGD was enhanced in cell lines that constitutively express integrin αvβ6, a known receptor for FMDV. In contrast, capsid expression in cattle-derived enriched APC populations was not enhanced by infection with this vector. Our data showed that vaccination with the two vectors yielded similar levels of protection against FMD in cattle. Although none of the vaccinated animals had detectable viremia, FMDV RNA was detected in serum samples from animals with clinical signs. Interestingly, CD4(+) and CD8(+) gamma interferon (IFN-γ)(+) cell responses were detected at significantly higher levels in animals vaccinated with Adt.O1C.2B.RGD than in animals vaccinated with Ad5.O1C.2B. Our results suggest that inclusion of an RGD motif in the fiber of Ad5-vectored FMD vaccine improves transgene delivery and cell-mediated immunity but does not significantly enhance vaccine performance in cattle.

Indexed as

Genetic VectorsAdenoviruses, HumanAnimalsAntibodies, ViralAntigen-Presenting CellsCapsid ProteinsCattleCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell LineFoot-and-Mouth DiseaseFoot-and-Mouth Disease VirusImmunity, CellularInterferon-gammaOligopeptidesRNA, ViralAntibodies, Viralarginyl-glycyl-aspartic acidCapsid ProteinsInterferon-gammaOligopeptidesRNA, ViralVaccines, SyntheticViral Vaccines

Identifiers

PMID26607309
PMCPMC4744924
OpenAlexW2253457396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.